Who Should NOT Take GLP-1 Medications?
US$ 28.86
retatrutide trial results october 2025 Lilly's triple agonist delivers up to 71.2 lbs of weight loss Triple hormone receptor agonist retatrutide
Description
Minimized Side Effects: Medical oversight helps manage side effects
Retatrutide is an investigational once-weekly triple agonist that simultaneously activates GLP-1, GIP, and glucagon receptors, distinguishing it from approved agents such as semaglutide and tirzepatide
Nonetheless, no significant increase in the risk of TOP was observed when the GLP1-RA group was compared with the overweight/obese reference group (HR, 1.79
That doesn't mean long-term success is out of reach
doi: 10.1002/oby.21107 25 VilsbllTKrarupTMadsbadSHolstJJ
Schwisow S, Falyar C, Silva S, Muckler VC
